Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.
Intramolecular hydrogen bonding is an important determinant of enzyme structure, catalysis, and inhibitor action. Monoacylglycerol lipase (MGL) modulates cannabinergic signaling as the main enzyme responsible for deactivating 2-arachidonoylglycerol (2-AG), a primary endocannabinoid lipid messenger. By enhancing tissue-protective 2-AG tone, targeted MGL inhibitors hold therapeutic promise for managing pain and treating inflammatory and neurodegenerative diseases. We report study of purified, solubilized human MGL (hMGL) to explore the details of hMGL catalysis by using two known covalent hMGL inhibitors, the carbamoyl tetrazole AM6701 and N-arachidonoylmaleimide (NAM), that act through distinct mechanisms. Using proton nuclear magnetic resonance spectroscopy (NMR) with purified wild-type and mutant hMGLs, we have directly observed a strong hydrogen-bond network involving Asp239 and His269 of the catalytic triad and neighboring Leu241 and Cys242 residues. hMGL inhibition by AM6701 alters this hydrogen-bonding pattern through subtle active-site structural rearrangements without influencing hydrogen-bond occupancies. Rapid carbamoylation of hMGL Ser122 by AM6701 and elimination of the leaving group is followed by a slow hydrolysis of the carbamate group, ultimately regenerating catalytically competent hMGL. In contrast, hMGL titration with NAM, which leads to cysteine alkylation, stoichiometrically decreases the population of the active-site hydrogen bonds. NAM prevents reformation of this network, and in this manner inhibits hMGL irreversibly. These data provide detailed molecular insight into the distinctive mechanisms of two covalent hMGL inhibitors and implicate a hydrogen-bond network as a structural feature of hMGL catalytic function.
Karageorgos
Ioannis
I
Center for Drug Discovery, Northeastern University, 116 Mugar Hall, Boston, MA 02115-5000, USA.
Tyukhtenko
Sergiy
S
Zvonok
Nikolai
N
Janero
David R
DR
Sallum
Christine
C
Makriyannis
Alexandros
A
D019943:Amino Acid Substitution / Q000235:genetics; D002384:Catalysis / Q000187:drug effects; D020134:Catalytic Domain / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D006860:Hydrogen Bonding / Q000187:drug effects; D066298:In Vitro Techniques; D007700:Kinetics; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008994:Monoacylglycerol Lipases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D016297:Mutagenesis, Site-Directed; D013777:Tetrazoles / Q000378:metabolism / Q000493:pharmacokinetics
C553459:AM 6701; D004791:Enzyme Inhibitors; D013777:Tetrazoles; D008994:Monoacylglycerol Lipases
J Med Chem. 2009 Dec 10;52(23):7410-20
19583260
J Clin Invest. 2008 Sep;118(9):3160-9
18677409
Br J Pharmacol. 2009 Jul;157(6):974-83
19486005
Anal Biochem. 2010 Apr 15;399(2):218-24
20015447
Biochemistry. 2007 May 22;46(20):6001-10
17455914
J Pharmacol Exp Ther. 2009 Sep;330(3):902-10
19502530
Assay Drug Dev Technol. 2008 Jun;6(3):387-93
18452392
J Mol Biol. 2010 Feb 26;396(3):663-73
19962385
FEBS Lett. 2002 Sep 25;528(1-3):203-6
12297305
Trends Pharmacol Sci. 2006 Mar;27(3):134-40
16476494
J Lipid Res. 2009 Jan;50(1):3-21
18952573
Curr Top Med Chem. 2008;8(3):247-67
18289091
Chem Biol. 2008 Aug 25;15(8):854-62
18721756
Nat Chem Biol. 2009 Jan;5(1):37-44
19029917
Eur J Med Chem. 2008 Jan;43(1):62-72
17452063
Chem Rev. 2006 Aug;106(8):3055-79
16895318
Eur J Neurosci. 2004 Jul;20(2):441-58
15233753
Chem Biol. 2007 Dec;14(12):1347-56
18096503
Cell. 2010 Jan 8;140(1):49-61
20079333
Life Sci. 2010 Apr 10;86(15-16):615-23
19527737
Chembiochem. 2010 Jan 25;11(2):218-27
19957260
Anal Biochem. 2010 Apr 1;399(1):132-4
20005861
Protein Sci. 2008 Dec;17(12):2023-37
18824507
Physiol Rev. 2009 Jan;89(1):309-80
19126760
Acc Chem Res. 2008 Feb;41(2):214-21
18281945
Mol Pharmacol. 2004 Nov;66(5):1260-4
15272052
J Proteome Res. 2008 May;7(5):2158-64
18452279
J Neurochem. 2007 Dec;103(5):1907-16
17868306
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
12136125
Chem Biol. 2005 Jun;12(6):649-56
15975510
Chem Phys Lipids. 2002 Dec 31;121(1-2):149-58
12505697
J Comput Aided Mol Des. 2009 Nov;23(11):799-806
19543978
Chem Biol. 2009 Jul 31;16(7):744-53
19635411
FASEB J. 2006 Mar;20(3):568-70
16403786
Biochim Biophys Acta. 2009 Jan;1791(1):53-60
19027877
Nat Chem Biol. 2009 Nov;5(11):808-14
19841630
Int Rev Psychiatry. 2009 Apr;21(2):122-33
19367506
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20270-5
19918051
Biofactors. 2009 Jan-Feb;35(1):88-97
19319851
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5424-7
18819796